title: Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin.
authors.affiliation: From the Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Avenue, Boston, MA 02215, USA The Harvard Medical School, Boston, MA, USA pridker@partners.org.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Ridker
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000378:metabolism; D008078:Cholesterol, LDL / Q000378:metabolism; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000517:prevention & control; D012008:Recurrence; D012307:Risk Factors; D014657:Vasculitis / Q000517:prevention & control*
chemical_list: D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D015415:Biomarkers; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors